Literature DB >> 22009281

Alzheimer disease: statins in the treatment of Alzheimer disease.

D Larry Sparks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009281     DOI： 10.1038/nrneurol.2011.165

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  7 in total

1.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

Authors:  D Larry Sparks; Marwan N Sabbagh; Donald J Connor; Jean Lopez; Lenore J Launer; Patrick Browne; Dawn Wasser; Sherry Johnson-Traver; Jeff Lochhead; Chuck Ziolwolski
Journal:  Arch Neurol       Date:  2005-05

2.  Reduced risk of incident AD with elective statin use in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Authors:  H H Feldman; R S Doody; M Kivipelto; D L Sparks; D D Waters; R W Jones; E Schwam; R Schindler; J Hey-Hadavi; D A DeMicco; A Breazna
Journal:  Neurology       Date:  2010-03-03       Impact factor: 9.910

4.  Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.

Authors:  Kerstin Bettermann; Alice M Arnold; Jeff Williamson; Stephen Rapp; Kaycee Sink; James F Toole; Michelle C Carlson; Sevil Yasar; Steven Dekosky; Gregory L Burke
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-01-14       Impact factor: 2.136

5.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Authors:  M Sano; K L Bell; D Galasko; J E Galvin; R G Thomas; C H van Dyck; P S Aisen
Journal:  Neurology       Date:  2011-07-27       Impact factor: 9.910

6.  Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Donald J Connor; Marwan N Sabbagh; Lisa M Sparks; Yushun Lin; Carolyn Liebsack
Journal:  Neurodegener Dis       Date:  2010-03-12       Impact factor: 2.977

7.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

Authors:  D L Sparks; D J Connor; M N Sabbagh; R B Petersen; J Lopez; P Browne
Journal:  Acta Neurol Scand Suppl       Date:  2006
  7 in total
  9 in total

1.  Evaluation of lovastatin effects on expression of anti-apoptotic Nrf2 and PGC-1α genes in neural stem cells treated with hydrogen peroxide.

Authors:  Alireza Abdanipour; Taki Tiraihi; Ali Noori-Zadeh; Arezo Majdi; Ramin Gosaili
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

2.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

Review 3.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 4.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

Review 5.  The mevalonate pathway in C. elegans.

Authors:  Manish Rauthan; Marc Pilon
Journal:  Lipids Health Dis       Date:  2011-12-28       Impact factor: 3.876

Review 6.  Therapy for Alzheimer's disease: Missing targets and functional markers?

Authors:  Milan Stoiljkovic; Tamas L Horvath; Mihály Hajós
Journal:  Ageing Res Rev       Date:  2021-03-09       Impact factor: 11.788

7.  Statins Inhibit Fibrillary β-Amyloid Induced Inflammation in a Model of the Human Blood Brain Barrier.

Authors:  Jarred M Griffin; Dan Kho; E Scott Graham; Louise F B Nicholson; Simon J O'Carroll
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

8.  A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion.

Authors:  Alvaro Sánchez-Ferro; Julián Benito-León; Alex J Mitchell; Félix Bermejo-Pareja
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-04       Impact factor: 2.570

9.  Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients.

Authors:  Rinko Grewal; Mona Haghighi; Shuai Huang; Amanda G Smith; Chuanhai Cao; Xiaoyang Lin; Daniel C Lee; Nancy Teten; Angela M Hill; Maj-Linda B Selenica
Journal:  Alzheimers Res Ther       Date:  2016-10-18       Impact factor: 6.982
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.